logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10786550 B1

PDFFull Text
Date of Patent:
Sep. 29, 2020

Filed:

May. 06, 2016

Blockade of ccl18 signaling via ccr6 as a therapeutic option in treating interstitial lung disease

Applicant:

Universitätsklinikum Freiburg, Freiburg, DE;

Inventors:

Gernot Zissel, Freiburg, DE;

Joachim Müller-Quernheim, Kirchzarten, DE;

Antje Prasse, Freiburg, DE;

Assignee:

Universitatsklinikum Freiburg, Freiburg, DE;

Attorney:

Jenkins, Wilson, Taylor & Hunt, P.A.

Primary Examiner:

Dong Jiang

Int. Cl.
CPC ...
A61K 38/16 (2006.01); A61K 38/17 (2006.01); G01N 33/68 (2006.01); G01N 33/574 (2006.01); A61K 9/00 (2006.01); C07K 14/715 (2006.01); A61K 45/06 (2006.01); C07K 14/00 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); C12N 15/113 (2010.01); C12N 15/115 (2010.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1793 (2013.01); A61K 9/0019 (2013.01); A61K 38/16 (2013.01); A61K 45/06 (2013.01); C07K 14/00 (2013.01); C07K 14/7158 (2013.01); C07K 16/24 (2013.01); C07K 16/2866 (2013.01); C12N 15/115 (2013.01); C12N 15/1136 (2013.01); C12N 15/1138 (2013.01); G01N 33/57423 (2013.01); G01N 33/6863 (2013.01); A61K 38/00 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2310/16 (2013.01); G01N 2333/521 (2013.01); G01N 2333/7158 (2013.01); G01N 2500/02 (2013.01); G01N 2800/12 (2013.01);
Abstract

The present invention relates to an isolated soluble CCR6 receptor polypeptide capable of binding to CCL18 and/or CCL20 and to a method for quantifying the concentration of a soluble CCR6 receptor polypeptide in a liquid sample from a subject. The present invention also relates to a method for detecting and/or prognosticating an interstitial lung disease or a cancer in a subject by determining the level of a soluble CCR6 receptor polypeptide in a sample from said subject and further provides a pharmaceutical composition comprising a compound capable of inhibiting the activity and/or the expression of CCL18 or CCL20 for the treatment of said diseases. The present invention further relates to an isolated polypeptide capable of binding to and inhibiting the activity of the chemokine receptor CCR6 and to a method for identifying further inhibitors of CCR6 receptor activity. The present invention also relates to a method for detecting an interstitial lung disease or a cancer in a subject by determining the level of CCR6 gene expression in a sample from said subject and further provides pharmaceutical compositions comprising inhibitors of CCR6 receptor activity and/or expression for the treatment of said diseases.

Find Patent Forward Citations

Loading…